Insulet (PODD) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Insulet (NASDAQ: PODD) recently:

• 10/12/2026 – Insulet had its price target lowered by Jefferies Financial Group Inc. from $275.00 to $190.00. They now have a “buy” rating on the stock.
• 10/10/2026 – Insulet was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/7/2026 – Insulet was upgraded by Barclays PLC to “hold”.
• 10/6/2026 – Insulet is now covered by Barclays PLC. They set an “equal weight” rating and a $150.00 price target on the stock.
• 9/21/2026 – Insulet had its “sell (d+)” rating reaffirmed by Weiss Ratings.

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.